Fernando Kreutz

Company: Cellvax

Job title: Chief Executive Officer

Seminars:

Leveraging Regulatory Momentum to Accelerate the Path to Approval for Personalized Cancer Vaccines 5:00 pm

• Strategically pursuing designations like Breakthrough Therapy or ISTs to validate early clinical signals, gain FDA partnership, and build external confidence in your platform’s viability • Using regulatory milestones to strengthen investor narratives by showcasing derisked development timelines, alignment with FDA expectations, and faster routes to market • Designing early trials with regulatory engagement in…Read more

day: Conference Day Two

Using the Patient’s Own Tumor to Eliminate Neoantigen Prediction & Redesign Clinical Trials 2:30 pm

• Deploying a unique mechanism that bypasses complex neoantigen prediction by letting the patient’s own tumor drive antigen presentation, eliminating the need for upfront epitope mapping • Cutting manufacturing costs and compressing turnaround to just three weeks by growing tumor-derived cells directly to avoid extensive sequencing, synthesis, and custom design • Targeting patients with minimal…Read more

day: Conference Day One